Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HMR's Allegra has 3.3% of new antihistamine Rxs, $1.9 mil. sales in second month on market -- Scott Levin.

Executive Summary

HOECHST MARION ROUSSEL ALLEGRA CAPTURES 3.3% OF NEW PRESCRIPTIONS dispensed in September for oral solid antihistamines, according to Scott-Levin's Source Prescription Audit. The 48,000 new prescriptions helped to generate $1.9 mil. in retail pharmacy sales for Allegra. Allegra, a metabolite of HMR's Seldane, was launched in August ("The Pink Sheet" Aug. 26, T&G-2).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029069

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel